Scholarlink

<p>Breast cancer is the most common cancer among women worldwide. To evaluate the real-world effectiveness of Neo-adjuvant chemotherapy (NACT) and adjuvant chemotherapy (ACT), we conducted a retrospective study comparing their impact on breast cancer prognosis. We retrieved data from the SEER database. We applied propensity score matching (PSM) to minimize confounding factors. Breast-cancer specific survival (BCSS) and overall survival (OS) were compared between the two groups. We also developed a nomogram prognostic model using clinicopathological parameters to predict survival rates. We identified 46,447 eligible patients in the SEER database. After PSM, 9,025 patients were included in each group, with 11,762 patients receiving NACT and 34,685 undergoing ACT before PSM. In the PSM cohort, the 5-year BCSS and OS were 88.3% (95% CI: 87.6–89.0%) and 85.7% (95% CI: 84.9–86.5%) for the NACT group, respectively. Notably, patients in the ACT group showed significantly better survival prognosis compared to those in the NACT group. We also developed nomograms to predict the 3-year, 5-year, and 8-year OS and BCSS rates for patients receiving NACT or ACT. Breast cancer patients who undergo surgery followed by ACT have a more favorable prognosis compared to those receiving NACT before surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of neoadjuvant and adjuvant chemotherapy on breast cancer prognosis in a propensity score matched population

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Ying Xu,
  • Bowen Liu,
  • Chang Chen,
  • Feng Mao,
  • Songjie Shen,
  • Xiaohui Zhang,
  • Xin Huang,
  • Yan Lin,
  • Yidong Zhou,
  • Qiang Sun

摘要

Breast cancer is the most common cancer among women worldwide. To evaluate the real-world effectiveness of Neo-adjuvant chemotherapy (NACT) and adjuvant chemotherapy (ACT), we conducted a retrospective study comparing their impact on breast cancer prognosis. We retrieved data from the SEER database. We applied propensity score matching (PSM) to minimize confounding factors. Breast-cancer specific survival (BCSS) and overall survival (OS) were compared between the two groups. We also developed a nomogram prognostic model using clinicopathological parameters to predict survival rates. We identified 46,447 eligible patients in the SEER database. After PSM, 9,025 patients were included in each group, with 11,762 patients receiving NACT and 34,685 undergoing ACT before PSM. In the PSM cohort, the 5-year BCSS and OS were 88.3% (95% CI: 87.6–89.0%) and 85.7% (95% CI: 84.9–86.5%) for the NACT group, respectively. Notably, patients in the ACT group showed significantly better survival prognosis compared to those in the NACT group. We also developed nomograms to predict the 3-year, 5-year, and 8-year OS and BCSS rates for patients receiving NACT or ACT. Breast cancer patients who undergo surgery followed by ACT have a more favorable prognosis compared to those receiving NACT before surgery.